New Therapies for rheumatoid arthritis

Medical Journal Armed Forces India

Volumn 59, Issue 2, 2003, Pages 90-92

  Kumar, A ^a   Marwaha, V ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRHEUMATIC AGENT; CELECOXIB; CHLOROQUINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; ETANERCEPT; ETORICOXIB; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; ROFECOXIB; SALAZOSULFAPYRIDINE; VALDECOXIB;

ALOPECIA; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIARRHEA; DRUG CONTRAINDICATION; DRUG COST; DRUG INDICATION; DRUG TOLERABILITY; EDITORIAL; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; MORTALITY; NAUSEA; NEPHROTOXICITY; NEWBORN; PANCYTOPENIA; PATHOGENESIS; RASH; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 0037395808     PISSN: 03771237     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0377-1237(03)80045-X     Document Type: Editorial

References (25)

1. Malaviya AN, Kapoor SK, Singh RR, Kumar A, Pande I. Prevalence of rheumatoid arthritis in the adult Indian Population. Rheumatol Int 1993;13:131-4.
2. Chopra A, Patil J, Billempelly V, Relwani J, Tandle HS. Prevalence of rheumatic diseases in a rural population in western India : a WHO-ILAR COPCORD study. J Assoc Physicians India. 2001;49:240-6.
3. Hochberg MC. Adult and juvenile rheumatoid arthritis : current epidemiologic concepts. Epidemiol Rev 1981;3:27-44.
4. Wolfe F, Cush JJ, O'Dell JR et al. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol 2001;28:1423-30.
5. Kremer JM. Rational use of new and existing disease modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134:695-706.
6. Moreland LW, Russel AS, Paulus HE. Management of rheumatoid arthritis : the historical context. J Rheumatol 2001;28:1431-52.
7. Moreland LW. Potential biologic agents for treating rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:445-91.
8. McInnes IB. Rheumatoid arthritis. From bench to bedside. Rheum Dis Clin North Am 2001;27:373-87.
9. Lard LR, Visser H, Speyer I et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis : comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
10. Egsmose C, Lund B, Borg G et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy : 5 - year follow-up of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13.
11. Van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995;34:74-8.
12. Symmons DPM, Jones MA, Scott DL, Prior P. Long-term mortality outcome in patients with rheumatoid arthritis : early presenters continue to do well. J Rheumatol 1998;25:1072-7.
13. Brater DC, Harris C, Redfern JS et al. Renal effects of COX-2 selective inhibitors. Am J Nephrol 2001;21:1-15.
14. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50.
15. Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis : a double blind, randomized, multicenter trial. European Study Group. Lancet 1999;353;259-66.
16. Emery P, Breedveld FC, Lemmel EM et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Multinational Leflunomide Study Group. Rheumatology (Oxford) 2000;39:655-65.
17. Kremer JM, Caldwell JR, Cannon GW et al. The combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone : a double -blind placebo controlled study (abstract). Arthritis Rheum 2000;44:S 224.
18. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor α monoclonal antibody combined with low dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
19. Kavanaugh A, St. Clair EW, McCune WJ et al. Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000;27:841-50.
20. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:;1098-04.
21. Felson DT, LaValley MP, Baldassare AR et al. The Prosorba column for treatment of refractory rheumatoid arthritis : a randomized double-blind, sham controlled trial. Arthritis Rheum 1999;42:2153-9.
22. Tilley BC, Alarcon GS, Heyse SP et al, Minocycline in rheumatoid arthritis : a 48 week, double-blind, placebo-controlled trial. Ann Intern Med 1995;122:81-8.
23. O'Dell JR, Paulsen G, Haire CE et al. Treatment of early seropositive rheumatoid arthritis with minocycline : four-year follow up of a double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:1691-5.
24. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993; (Suppl 8):S 117-9.
25. De Vita S, Zasa F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis : evidence for a pathogenetic role of B cells. Arthritis Rheum 2000;46:2029-33.